Sustained virologic response for chronic hepatitis C infection after 27 days of treatment with sofosbuvir and ribavirin

Open Forum Infectious Diseases

Volumn 1, Issue 1, 2014, Pages

  Meissner, Eric G ^a   Nelson, Amy ^a   Marti, Miriam ^a   Masur, Henry ^b   Osinusi, Anu ^a,c   Kottilil, Shyam ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis C virus; Interferon free treatment; Sofosbuvir; Sustained virologic response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; RIBAVIRIN; SOFOSBUVIR;

ADULT; ANXIETY; ARTICLE; BLOOD SAMPLING; CASE REPORT; CHRONIC HEPATITIS C; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MIDDLE AGED; MORNING DOSAGE; PHLEBOTOMY; PRIORITY JOURNAL; SUSTAINED VIROLOGIC RESPONSE; VIRUS LOAD;

EID: 84921523897     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu013     Document Type: Article

References (8)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-42.
2. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368:1907-17.
3. Casey LC, Lee WM. Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol 2013; 29:243-9.
4. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-77.
5. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310:804-11.
6. Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL27B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45:164-71.
7. Guedj J, Perelson AS. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011; 53:1801-8.
8. Meissner EG, Bon D, Prokunina-Olsson L, et al. IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis c, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 2014. PMID: 24367041.